A method for treatment of neurodegenerative 
disease conditions 
stemming from 
multiple sclerosis, aging, autoimmune diseases and 
fibromyalgia. A compound effective to increase neuronal 
metabolism of 
histamine to a 
histamine H2 
agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain 
myelin against undergoing self-degeneration. The compound is selected from the group consisting of 
histamine M-
methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and 
histamine H3 antagonists. The histamine M-
methyltransferase may be administered to increase neuronal 
metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A 
agonist may be administered so as to increase neuronal 
metabolism of telemethylhistamine to an H2 
agonist. Separately or in conjunction with the others, the 
histamine H3 
antagonist may be administered so as to inhibit metabolism of the telemethylhistamine to an H3 agonist, thereby increasing metabolism of the telemethylhistamine to an H2 agonist. The increased 
histamine H2 agonist levels reduce demyelination and the symptoms that are associated with these conditions.